How to Optimize Goal-Directed Medical Therapy (GDMT) in Patients with Heart Failure.

IF 4.3 3区材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC

ACS Applied Electronic Materials Pub Date : 2024-09-01 Epub Date: 2024-08-02 DOI:10.1007/s11886-024-02101-x

Emily Newman, Chukwuemezie Kamanu, Gregory Gibson, Yevgeniy Brailovsky

{"title":"How to Optimize Goal-Directed Medical Therapy (GDMT) in Patients with Heart Failure.","authors":"Emily Newman, Chukwuemezie Kamanu, Gregory Gibson, Yevgeniy Brailovsky","doi":"10.1007/s11886-024-02101-x","DOIUrl":null,"url":null,"abstract":"Purpose of review: Heart failure is a clinical syndrome with signs and symptoms from underlying cardiac abnormality and evidence of pulmonary or systemic congestion on laboratory testing or other objective findings (Bozkurt et al. in Eur J Heart Fail 23:352-380, 2021). Heart failure with reduced ejection fraction (HFrEF), when heart failure is due to underlying reduction in ejection fraction to <math><mo>≤</mo></math> 40. The goal of this review is to briefly describe the mechanisms and benefits of the various pharmacological interventions described in the 2022 AHA/ACC/HFSA Guidelines focusing on Stage C: Symptomatic Heart Failure HFrEF, while providing basic guidance on safe use of these medications.Recent findings: Use of medications from each class as recommended in the 2022 Guidelines can provide significant morbidity and mortality benefits for our patients. Despite advances in therapeutics for patients with HFrEF, patients are frequently under treated and more research is needed to help optimize management of these complicated patients.","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11379751/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11886-024-02101-x","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Heart failure is a clinical syndrome with signs and symptoms from underlying cardiac abnormality and evidence of pulmonary or systemic congestion on laboratory testing or other objective findings (Bozkurt et al. in Eur J Heart Fail 23:352-380, 2021). Heart failure with reduced ejection fraction (HFrEF), when heart failure is due to underlying reduction in ejection fraction to $\leq$ 40. The goal of this review is to briefly describe the mechanisms and benefits of the various pharmacological interventions described in the 2022 AHA/ACC/HFSA Guidelines focusing on Stage C: Symptomatic Heart Failure HFrEF, while providing basic guidance on safe use of these medications.

Recent findings: Use of medications from each class as recommended in the 2022 Guidelines can provide significant morbidity and mortality benefits for our patients. Despite advances in therapeutics for patients with HFrEF, patients are frequently under treated and more research is needed to help optimize management of these complicated patients.

Abstract Image

查看原文本刊更多论文

如何优化心力衰竭患者的目标导向医疗疗法 (GDMT)。

审查目的：心力衰竭是一种临床综合征，具有潜在心脏异常引起的症状和体征，以及实验室检查或其他客观发现的肺部或全身充血证据（Bozkurt 等，载于 Eur J Heart Fail 23:352-380, 2021）。射血分数降低型心衰（HFrEF），即射血分数降低至≤40的潜在心衰。本综述旨在简要介绍 2022 年 AHA/ACC/HFSA 指南中所述各种药物干预的机制和益处，重点关注 C 阶段：症状性心力衰竭 HFrEF，同时提供安全使用这些药物的基本指导：根据《2022 年指南》的建议使用各类药物可为患者带来显著的发病率和死亡率方面的益处。尽管针对 HFrEF 患者的治疗方法不断进步，但患者往往得不到充分治疗，因此需要开展更多研究，以帮助优化对这些复杂患者的管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Electronic Materials Multiple-

CiteScore

7.20

自引率

4.30%

发文量

567